Welcome to Greenshoots
Greenshoots is a collection of fresh intellectual property insight, analysis and commentary on the issues that matter most to those who invent, manage and protect intellectual property, written by the IP specialists of Appleyard Lees.
Now that you’re here, why not take a look around?
Non-Fungible Tokens: digital commercialisation with caveats
What are non-fungible tokens (NFTS) and what are the copyright issues around owning an NFT?
Protecting IP in plant-based ‘meat-substitutes’
Innovation in the plant-based meat sector is aiming to help to solve some of the problems associated with animal-meat production.
The Greenshoots Podcast by Appleyard Lees – episode 23: Routes into a career as an IP attorney
In this episode of the podcast, we are joined by trade mark attorney Cherry Shin and trainee patent attorney Jonathan Foster to discuss careers in IP.
Protecting IP in lab-grown organs – organoids
Lab-grown miniature organs (also known as organoids) is a technology area that has the potential to significantly lower costs and failure rates in drug development, and to improve safety.
Inside Green Innovation: Progress Report
What can patent data reveal about global progress in green innovation, and what might be achieved in years to come?
The Greenshoots Podcast by Appleyard Lees – episode 22: When to go to the IPEC – IP litigation in the UK
Appleyard Lees solicitors, Bill Lister and Chris Thomas, discuss when a case should be taken to the IPEC, the mechanisms for doing so, and what proceedings may look like once a case reaches the IPEC.
Who are the players in the digital healthcare space for medicine development? An analysis of patent filing trends
In this article, we look at some of the recent patenting trends and challenges in the digital healthcare space, with a spotlight on digital healthcare for medicine development.
Licence agreements and European patent opposition proceedings
After a potential opponent has decided to prepare an opposition, there are good reasons to also consider approaching the patent owner to try to negotiate a licensing agreement.
G2/21 – Plausibility
A new EPO referral to the enlarged BoA will determine whether post-filed data can be used to support inventive step and plausibility.
